Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Vaccines

Free Subscription 14.09.2026 1 Arch Virol 2 J Infect 2 Lancet 1 Nat Med 3 PLoS One 1 Proc Natl Acad Sci U S A 29 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Arch Virol

1. LIU X, Fang E, Xu H, Liu X, et al
   Immunogenicity of a Vero cell-adapted Japanese encephalitis attenuated virus strain SA14-14-2 VC(6).
   Arch Virol. 2026;171:276.
   PubMed         Abstract available
   
   

   
   J Infect

2. MAZARAKIS N, Toh ZQ, Neal E, Nguyen C, et al
   Corrigendum to 'Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia' [J Infect 92 (2026)/106727].
   J Infect. 2026;93:106851.
   PubMed        
   
   
3. MAZARAKIS N, Toh ZQ, Neal E, Bright K, et al
   Corrigendum to "The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose" [J Infect 90 (2025)/106447].
   J Infect. 2026;93:106850.
   PubMed        
   
   

   
   Lancet

4. DOSHI RH, Lubega I, Muhoza P, Carlock G, et al
   Immunogenicity of fractional one-fifth and one-half doses of 17DD yellow fever vaccine compared with full dose in children aged 9-23 months in Uganda: a phase 4, single-blind, randomised clinical trial.
   Lancet. 2026 Sep 11:S0140-6736(26)01390-5. doi: 10.1016/S0140-6736(26)01390.
   PubMed         Abstract available
   
   
5. PRASAD AN, Geisbert TW
   rVSVDeltaG-ZEBOV-GP vaccine-induced seroreactivity to Bundibugyo virus: a cross-protection dilemma.
   Lancet. 2026;408:973-976.
   PubMed        
   
   

   
   Nat Med

6. SALEM JE, Curmin R, Ajrouche A, De Rycke Y, et al
   COVID-19 vaccination around immune checkpoint inhibitor start and survival in a nationwide cohort of patients with cancer.
   Nat Med. 2026 Sep 10. doi: 10.1038/s41591-026-04640.
   PubMed         Abstract available
   
   

   
   PLoS One

7. SOUSA IO, Leite JLP, Melo AODS, Monteiro ASS, et al
   Nasopharyngeal carriage of Streptococcus pneumoniae in children aged two to five years old in the conjugate vaccine era: A cross-sectional study in Salvador, Brazil.
   PLoS One. 2026;21:e0357903.
   PubMed         Abstract available
   
   
8. ALDILA D, Rahman NS, Majere A, Fatmawati, et al
   Mathematical modeling of HBV-HDV transmission with superinfection: The role of vaccination and liver transplantation in disease dynamics.
   PLoS One. 2026;21:e0356725.
   PubMed         Abstract available
   
   
9. NAUMAN RW, Greer PA, Craig AW, Cotechini T, et al
   Differential effects of BCG-Russia and BCG-TICE on trained immunity: Potential implications for bladder cancer immunotherapy.
   PLoS One. 2026;21:e0357950.
   PubMed         Abstract available
   
   

   
   Proc Natl Acad Sci U S A

10. LADAK RJ, Pelin A, Zhuang H, Abboud C, et al
    The 4EHP/GIGYF2 translation repressor complex is co-opted by the vaccinia virus K3L protein as a potential mechanism of immunoevasion.
    Proc Natl Acad Sci U S A. 2026;123:e2618090123.
    PubMed         Abstract available
    
    

    
    Vaccine

11. APPELQVIST E, Lof E, Kuhlmann-Berenzon S, Ploner A, et al
    Determinants associated with lower HPV vaccination uptake in the school-based program for girls - A follow-up of the Swedish National Immunization Program, 2013-2023.
    Vaccine. 2026;92:129083.
    PubMed         Abstract available
    
    
12. SORDO-PUGA Y, Sardina-Gonzalez T, Perez-Perez D, Wong-Rodriguez L, et al
    Herd immunity without evidence of viral circulation during seven years of vaccination with Porvac(R), a subunit vaccine against classical swine fever.
    Vaccine. 2026;92:129157.
    PubMed         Abstract available
    
    
13. SHAO Y, Xie Z, Wang R
    T-cell immunity in human herpesvirus vaccine development: research advances and translational challenges.
    Vaccine. 2026;92:128992.
    PubMed         Abstract available
    
    
14. LIU C, Ma P, Li J, Li W, et al
    Effective protection against PRRSV NADC30 by recombinant chimpanzee adenovirus vaccines expressing GP35 or M-GP5 fusion proteins.
    Vaccine. 2026;92:129158.
    PubMed         Abstract available
    
    
15. HOLLIDAY RC, Darkwa A, Brooks GA, Akintobi TH, et al
    Developing counter-narratives to address COVID-19 misinformation among 18-24 year olds in community and campus settings.
    Vaccine. 2025;60 Suppl 1:127135.
    PubMed         Abstract available
    
    
16. BUCKLIN R, Gauthreaux N, Faber E, Askelson N, et al
    Listening to micropolitan community leaders to support pandemic response efforts.
    Vaccine. 2025;60 Suppl 1:127255.
    PubMed         Abstract available
    
    
17. HERMANN E, Krammer F
    The return of H1N1: Reemergence of the influenza virus A subtype H1N1 in 1977.
    Vaccine. 2026;91:128963.
    PubMed         Abstract available
    
    
18. ZHANG Z, Chen Y, Fan W, Qi X, et al
    Recombinant Marek's disease virus expressing the VP2 gene provides effective protection against novel variant infectious bursal disease virus.
    Vaccine. 2026;91:129028.
    PubMed         Abstract available
    
    
19. SRIUDOMPORN S, Patenaude B
    Quantifying the cost of measles outbreaks in the U.S. and how costs scale with outbreak size.
    Vaccine. 2026;91:129040.
    PubMed         Abstract available
    
    
20. KIM SJ, Kim HW, Son SE, Song JH, et al
    Wuhan-ancestral multi-antigen SARS-CoV-2 virus-like particles protect against the omicron sublineage JN.1 variant.
    Vaccine. 2026;91:129059.
    PubMed         Abstract available
    
    
21. RANJAN R, Anwari P, Colson A, van der Meer R, et al
    Measles outbreak risk in Afghanistan: provincial immunity gaps and epidemic potential following immunisation system disruption.
    Vaccine. 2026;91:129078.
    PubMed         Abstract available
    
    
22. MONOI A, Endo A, Kriznar M, Suzuki M, et al
    Comparing the potential impacts of seasonal immunisation against year-round immunisation to prevent RSV infant hospitalisations in Japan: A modelling study.
    Vaccine. 2026;91:129079.
    PubMed         Abstract available
    
    
23. PANT D, Zhang Y, Feaheny F, Kim YC, et al
    Persistence of immune responses 5 years after vaccination with a single dose of typhoid conjugate vaccine (TCV) in Nepalese children.
    Vaccine. 2026;92:129130.
    PubMed         Abstract available
    
    
24. OKHOLM AK, Fougeroux C, Hagen SH, Paludan SR, et al
    Virus-like particle display of the SARS-CoV-2 receptor-binding domain using a modular tag/catcher system enhances immunogenicity of a DNA vaccine in mice.
    Vaccine. 2026;92:129117.
    PubMed         Abstract available
    
    
25. C M, Dymock M, Flanagan KL, Plebanski M, et al
    The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults.
    Vaccine. 2026;92:129034.
    PubMed         Abstract available
    
    
26. ONISHI S, Suzuki Y, Sugimoto K, Otsuka A, et al
    Improving intradermal dosing consistency in mice using a hollow microneedle: A model study with a SARS-CoV-2 mRNA vaccine.
    Vaccine. 2026;92:129111.
    PubMed         Abstract available
    
    
27. PALMSTEN K, Cao J, Vazquez-Benitez G, Ehresmann K, et al
    Assessment of infant growth and health care utilization following tetanus, diphtheria, pertussis (Tdap) vaccination during pregnancy and lactation.
    Vaccine. 2026;92:129123.
    PubMed         Abstract available
    
    
28. SANBORN J, Robertson MM, Penrose K, Rane M, et al
    Gaps between willingness and uptake of influenza and COVID-19 vaccines during the 2025-26 respiratory virus season in a U.S. adult cohort.
    Vaccine. 2026;92:129126.
    PubMed         Abstract available
    
    
29. LU J, Ouyang Z, Huang F, Xie X, et al
    Real-world effectiveness of the influenza vaccine among school-aged children in Shenzhen, China, 2024-2025 season: A test-negative design study.
    Vaccine. 2026;92:129100.
    PubMed         Abstract available
    
    
30. CHECCHI M, Panwar K, French CE, Mohammed H, et al
    Impact of the HPV vaccination programme on anal HPV infection in gay, bisexual and other men who have sex with men: multi-site enhanced surveillance study in specialist sexual health services in England.
    Vaccine. 2026;92:129114.
    PubMed         Abstract available
    
    
31. UGWU OP, Okon MB, Ogenyi FC, Ugwu JN, et al
    Digital twins and explainable AI across the vaccine life cycle: from mRNA manufacturing to thermostability, cold-chain logistics, and immunisation services.
    Vaccine. 2026;92:129131.
    PubMed         Abstract available
    
    
32. THAKKAR V, Aryan Y, Gautam S, Joshi R, et al
    Influence of vaccine delivery route on immune imprinting in influenza vaccination.
    Vaccine. 2026;92:129109.
    PubMed         Abstract available
    
    
33. KALYANASUNDARAM A, Kifle DW, Davis J, Balkhi MY, et al
    Antibody-mediated functional responses induced by the SchistoShield(R) schistosomiasis vaccine in disease-naive and endemic human populations.
    Vaccine. 2026;92:129129.
    PubMed         Abstract available
    
    
34. ALMEIDA MG, Alves de Oliveira BF, de Melo Junior EB, de Araujo Rodrigues AR, et al
    Knowledge as a predictor of parental vaccine hesitancy during children's first year of life.
    Vaccine. 2026;92:129127.
    PubMed         Abstract available
    
    
35. DESAI M, Cardona J, Khetan S, Mehta S, et al
    Safety and immunogenicity of mRNA-1345 revaccination at least 12 months following primary vaccination with a licensed protein subunit RSV vaccine.
    Vaccine. 2026;92:129068.
    PubMed         Abstract available
    
    
36. PAHLMAN K, Silva DS
    Vaccine mis- and disinformation and the illusion of autonomy.
    Vaccine. 2026;92:129103.
    PubMed        
    
    
37. KUNISHIMA Y, Senpuku K, Taniguchi K, Kataoka-Nakamura C, et al
    Linker-mediated single-transcript mRNA vaccine expressing virus-like particles of enterovirus D68.
    Vaccine. 2026;92:129136.
    PubMed         Abstract available
    
    
38. KHATRI B, Salguero FJ, Goyal M, Dagg B, et al
    Understanding pathogenesis of and BCG vaccine efficacy against high, moderate, and low transmissible Mycobacterium tuberculosis strains in mice.
    Vaccine. 2026;92:129116.
    PubMed         Abstract available
    
    
39. AMADO-GOMES AC, Climaco MC, Cirilo TM, Santos FV, et al
    Heterologous adenovirus A2/Leish-Tec(R) vaccination strategy in a murine model of visceral leishmaniasis: Potential canine vaccine with enhanced protection and potent T-cell immunity.
    Vaccine. 2026;92:129105.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum